Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers
J. Clin. Invest. Patrick C.H. Hsieh, et al. 116:237 doi:10.1172/JCI25878 [
Go to this article.]
Figure 2PDGF-BB prevents cardiomyocyte apoptosis via PI3K/Akt signaling. (
A) Cardiomyocytes were treated with doxorubicin and PDGF-BB in concentrations as indicated (ng/ml). Apoptosis was determined by DNA fragmentation cytometry. (
B) Immunoblotting of phospho–PDGFR-β (p–PDGFR-β), total PDGFR-β, phospho–Akt (p-Akt), or total Akt in cardiomyocytes treated with 10 ng/ml PDGF-AA or PDGF–BB. The dose (ng/ml) and time (10 ng/ml PDGF-BB) effects of phosphorylation of PDGFR-β and Akt by PDGF-BB are also shown. (
C) Immunofluorescence staining of PDGFR-β phosphorylation and internalization in cardiomyocytes (yellow) treated with PDGF-BB. Red, p–PDGFR-β; green, α-sarcomeric actinin (α-SA); blue, DAPI. (
D) Immunoblotting of phospho-Akt and total Akt and apoptosis in cardiomyocytes treated with PDGF-BB, LY294002 (LY), and GFP adenovirus (Control) or dominant-negative Akt (dnAkt) adenovirus. **
P < 0.001.
